Chicago, IL, United States of America

Joel Bergman

This inventor holds 7 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents. Top assignees: University of Illinois, H. Lee Moffitt Cancer Center and Research Institute, Inc., The Children's Hospital of Philadelphia. Active years: 2016-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joel Bergman. Retrieved from https://idiyas.com/inventor/joel-bergman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

 

Average Co-Inventor Count = 4.8

ph-index = 3

Forward Citations = 69(Granted Patents)


Company Filing History:


Years Active: 2016-2019

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Joel Bergman - Innovative Inventor from Chicago

Introduction: Joel Bergman is a renowned inventor based in Chicago, Illinois, known for his groundbreaking contributions to various industries.

Latest Patents: Joel Bergman holds several patents in the fields of technology, healthcare, and consumer products, showcasing his diverse range of innovative ideas.

Career Highlights: With a career spanning over two decades, Joel Bergman has established himself as a visionary inventor with a keen eye for identifying gaps in the market and creating solutions through his inventions.

Collaborations: Throughout his career, Joel Bergman has collaborated with leading companies, research institutions, and universities to bring his inventions to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Joel Bergman's passion for innovation and his relentless drive to push the boundaries of what is possible make him a standout figure in the world of inventors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…